ANI Pharma (ANIP) Tops Q1 EPS by 12c, Offers FY16 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
ANI Pharmaceuticals (ANIP) PT Lifted to $55 at Guggenheim
May 5, 2016 10:18 AM EDTGuggenheim analyst Louise Chen reiterating Buy rating and boosted his price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $55.00 (from $50.00) following Q1 beat. The analyst sees many potential catalysts in 2Q16+.
Chen commented, "Post the 1Q16 beat, we remain positive on ANIP and... More
